patients with diabetes. A direct comparison of olmesartan and telmisartan at standard doses was previously performed in a crossover study after switching from valsartan to assess the antihypertensive effect, metabolic parameters, high molecular weight adiponectin (HMWadiponectin) and highly sensitive C-reactive protein (hs-CRP) [9] . In addition, the effect on the home blood pressure and metabolic parameters was investigated in hypertensive patients with heart failure and metabolic syndrome [10] . However, the efficacy of high-dose therapy with ARBs in type 2 diabetes has not been reported. In the blood pressure lowing effect, olmesartan shows diabetic patients on insulin therapy; 2) diabetic patients with unstable glycemic control; 3) secondary hypertension; 4) dialysis; 5) pregnancy or possible pregnancy (in women); 6) a history of hypersensitivity to any of the ingredients of the study drug; 7) serious hepatic disease; 8) serious renal disease (serum creatinine ≥3 mg/dL); and 9) any other reason judged by the attending physician to make the patient inappropriate for the study. The hospital ethics committee approved this protocol, and informed consent was obtained from each subject.
Study design
As shown in Fig. 1 , the primary endpoint (blood pressure reduction rate) and the secondary endpoints [body mass index (BMI), parameters of glucose metabolism [HbA1c (NGSP), FPG, FIRI, HOMA-IR and HMWadiponectin], inflammatory marker (hs-CRP), and serum lipids (TC, LDL-C, HDL-C, and TG)] were measured in Weeks 0, 12, and 24. Drugs were switched in Week 12 to investigate the changes that occurred. Olmesartan group (n=36) show A (n=19) and D (n=17), and telmisartan group (n=36) indicate B (n=19) and C (n=17).
The BP measurement was made three times by doctors using sphygmomanometers in the sitting position for outpatients, and we used the average of those.
Concomitant drugs were not changed to non-specia strong antihypertensive effect by high selectivity and strong binding to AT1 receptors [11] , while telmisartan has been reported to have a more sustained antihypertensive effect by a longer residence time on AT1 receptors [12] [13] [14] . Furthermore, in metabolism olmesartan has an inflammatory effect as pleiotropic effects [15] [16] [17] , while telmisartan has reported to increase serum adiponectine as a partial PPAR-γ agonist at the highest dose [18] . Therefore, a crossover study was performed to compare the effects of olmesartan (40 mg/day) and telmisartan (80 mg/day) on the blood pressure and metabolic profile.
subjects and Methods

Subjects
The subjects were male and female outpatients with type 2 diabetes aged over 20 years and under 80 years old (20 men and 16 women) who did not achieve the target of blood pressure <130/80 mmHg following treatment with olmesartan at 40 mg/day or telmisartan at 80 mg/day for 8 weeks or more. The target of blood pressure bases on the guideline for treatment of hypertension of the Japanese Society of Hypertension (JSH 2009). The patients gave consent to participation in this study and their other drugs were not changed for 8 weeks before registration. Exclusion criteria were: 1)
Fig. 1 Schematic representation of the study design
The study protocol is shown in this schematic diagram. Measurement of blood pressure and blood sample were performed at 0W, 12W and 24W for evaluation of each medication. Olmesartan group (n=36): A (n=19) and D (n=17), telmisartan group (n=36): B (n=19) and C (n=17). W, week.
fied drugs during the study (the observation and treatment periods). All adverse events (subjective and objective symptoms and abnormal laboratory data), including dizziness, hypotension, and hepatic dysfunction, that were encountered during the study period were investigated to determine their nature, timing of remission, severity, actions taken, outcome, seriousness, and causal relation with the study drug. This information was recorded in the medical charts. Follow up was performed when necessary. The demographic data of the 36 patients (20 men and 16 women) are shown in Table 1 . The age was 68.3±9.8 years, body weight was 65.7±14.4 kg, BMI was 25.7±4.7 kg/m 2 , and duration of diabetes was 11.7±6.9 years. Complications were dyslipidemia in 14 patients, cerebrovascular disease in 5 patients, ischemic heart disease in 3 patients, and arteriosclerosis obliterans in 2 patients. Concomitant drugs included antihypertensive agents (calcium antagonists in 16 patients, α1-blockers in 2 patients, and diuretics in 1 patient, with some patients on multiple drugs), antidiabetic agent (sulfonylureas in 19 patients, α-Glucosidase inhibitors in 9 patients, biguanides in 8 patients, pioglitazones in 7 patients, and glinides in 1 patient), and lipid-lowering agents (statins in 7 patients). Table 2 shows the baseline data of study subjects in olmesartan *p values by ANOVA for differences between data in olmesartan group and in telmisartan group. FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density; hs-CRP, highly sensitive C-reactive protein; HMW-adiponectin, high molecular weight adiponectin; SBP, systolic blood pressure; DBP, diastolic blood pressure; W, week. 
Statistical analysis
ANOVA was used for the baseline data and absolute value after treatment of both groups and Friedman's test was used to compare percent change. Spearman's correlation coefficients were calculated to evaluate significant relationships. Differences were considered to be statistically significant at a value of p<0.05.
Results
As shown in Table 3 , the blood pressure in olmesartan group (A 12W and D 24W) and in telmis- and of telmisartan group (lower) in blood pressure, b. Percent changes of blood pressure in the two Groups. a.*p values by ANOVA for differences between data of baseline and 12W used for evaluation of drug, and differences between data in the two Groups. b. **p values by Friedman's test for differences between data in the two Groups. SBP, systolic blood pressure; DBP, diastolic blood pressure. *p values by ANOVA for differences between data of baseline and 12W used for evaluation in the two Groups. FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density; hs-CRP, highly sensitive C-reactive protein; HMW-adiponectin, high molecular weight adiponectin. test for differences between data in the two Groups. FPG, fasting plasma glucose ; FIRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density; hs-CRP, highly sensitive C-reactive protein; HMW-adiponectin, high molecular weight adiponectin. not possible, but the patients did not achieve the target antihypertentive effect even at high ARB doses. We consider that there are some reasons for no significant difference between the two groups in blood pressure. First, while the average of systolic blood pressure of the subjects is only 5~7mmHg higher than the target (130mmHg), and the average of diastolic blood pressure is lower than the target (80mmHg). Second, the baseline of blood pressure is not accomplished the target in spite of using high-dose ARB in combination with calcium antagonists in 16 patients. Third, olmesartan shows high selectivity and strong binding to AT1 receptors [11] , while telmisartan has been reported to have a longer residence time on AT1 receptors that contributes to a more sustained antihypertensive effect [12] [13] [14] .
Improvement of glycemic control, insulin resistance, and HDL-C was observed in olmesartan group compared with telmisartan group. However, there is no difference of HMW-adiponectin between olmesartan group and telmisartan group in this study. Telmisartan has been reported to increase HMW-adiponectin by activation of PPAR-γ [19] [20] [21] . No difference has been reported in the level of HMW-adiponectin with administration of a standard dose [9] , but the increase of HMW-adiponectin mediated by olmesartan in this study might be related to factors other than PPAR-γ. First, olmesartan has a strong hydrogen bond between its hydroxylisopropyl group (OH group) at position 4 of the imidazole ring and a carboxyl group (COOH group) at position 5 of this ring [22] [23] [24] . Because it is group both in terms of the absolute value (p=0.023) and percent change (p=0.017). Furthermore, other markers are shown in Tables 4 and 5. The hs-CRP level was 1162.1±1605.3 in olmesartan group versus 1609.6±2840.0 mg/mL in telmisartan group and its percent change was 23.3±146.8 versus 112.9±430.7, with a decrease being seen in olmesartan group. There was difference of HMW-adiponectin levels (8.8±7.6 versus 8.0±6.3 μg/mL), and a significant increase (p=0.021) was seen in olmesartan group, but the percent change was not different (8.2±24.5 versus 4.1±26.2). There were no differences of body weight (BMI) in terms of both the absolute value and the percent change (data not shown). A positive correlation was observed between the percent change of HOMA-IR and hs-CRP in olmesartan group (r=0.39, p<0.05) (Fig. 2) .
Discussion
In this study, no difference was found between olmesartan group and telmisartan group with respect to the antihypertentive effect on the blood pressure measured at outpatient visits, and a comparable antihypertentive effect of the two drugs was observed. When the mean blood pressure over 24-hr was measured by ABPM, a standard dose of olmesartan significantly improved the blood pressure compared with telmisartan for both systolic and diastolic pressures [9] . In the present study, ABPM was not employed and accurate comparison was the present study.
In conclusion, the antihypertensive effect of highdose olmesartan and telmisartan was comparable in hypertensive patients with type 2 diabetes, but olmesartan was suggested to be superior in terms of improving glucose metabolism, insulin resistance, and lipid metabolism.
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reported to have a strong inhibitory effect on the RAS, olmesartan might have improved insulin sensitivity in this study through an increase of HMW-adiponectin. Second, hs-CRP was significantly lower in olmesartan group compared with telmisartan group at standard doses [9] , and hs-CRP decreased in olmesartan group during this study (although not significantly). Also, a correlation was observed between the percent change of HOMA-IR and hs-CRP. These results suggest that the anti-inflammatory action of olmesartan (one of its pleiotropic effects) might have helped to improve insulin sensitivity. In other study, it was reported that dual blockade of Ang II with ACE-I and ARB, but not a double dosage of ACE-I significantly decreased the relative value of hs-CRP at the end of the study compared with that at the beginning in hypertensive patients with type 2 diabetes [25] .
The RAS has vasopressor and organ protective effects mediated by the AT1R and Ang II, but the ACE2-Ang-(1-7) system also has vasopressor and organ protective effects unlike those of Ang II [26, 27] . With respect to organ protection, olmesartan was reported to have a cardioprotective effect by improving the coronary artery wall/lumen ratio and perivascular fibrosis by increasing ACE-Ang-(1-7) via enhancement of ACE2 [28] . It also has a renoprotective effect [29, 30] , and it increases insulin secretion and suppresses apoptosis of β-cells in diabetic mice [31, 32] . Increased activity of the ACE2-Ang-(1-7) system might be involved in improvement of insulin sensitivity, although this could not be confirmed because ACE2 was not measured in
